Actinium Pharmaceuticals Inc. (ATNM) Given “Buy” Rating at Roth Capital
Roth Capital reaffirmed their buy rating on shares of Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) in a research report sent to investors on Wednesday. They currently have a $5.00 price target on the stock.
ATNM has been the topic of a number of other reports. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a hold rating to a buy rating and set a $2.00 price target on the stock in a research note on Monday, June 6th. FBR & Co reissued a buy rating on shares of Actinium Pharmaceuticals in a research note on Thursday, June 30th. Finally, HC Wainwright reissued a buy rating on shares of Actinium Pharmaceuticals in a research note on Thursday, June 2nd.
Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 1.70 on Wednesday. The firm’s 50-day moving average is $1.72 and its 200-day moving average is $1.81. The stock’s market capitalization is $81.12 million. Actinium Pharmaceuticals has a 52 week low of $1.60 and a 52 week high of $3.50.
In other news, major shareholder Sloan-Kettering Cance Memorial sold 192,927 shares of the business’s stock in a transaction that occurred on Wednesday, August 31st. The shares were sold at an average price of $1.83, for a total value of $353,056.41. Following the completion of the transaction, the insider now owns 4,878,988 shares of the company’s stock, valued at $8,928,548.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. increased its stake in Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock worth $819,000 after buying an additional 47,131 shares during the last quarter. BlackRock Fund Advisors increased its stake in Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock worth $181,000 after buying an additional 24,453 shares during the last quarter. Vanguard Group Inc. increased its stake in Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock worth $2,798,000 after buying an additional 254,318 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Actinium Pharmaceuticals during the second quarter worth about $247,000.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Stock Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.